Subthalamic neurostimulation for Parkinson's disease with early fluctuations: Balancing the risks and benefits

The Lancet Neurology

Volumn 12, Issue 10, 2013, Pages 1025-1034

  Deuschl, Günther ^a   Agid, Yves ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

APATHY; BRAIN HEMORRHAGE; CONFUSION; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DYSKINESIA; FOLLOW UP; GLOBUS PALLIDUS; HOEHN AND YAHR SCALE; META ANALYSIS (TOPIC); MICROELECTRODE; MORTALITY; MOTOR PERFORMANCE; NERVE CELL NECROSIS; NERVE STIMULATION; NOTE; OUTCOME ASSESSMENT; PARKINSON DISEASE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SOCIAL PSYCHOLOGY; SUBTHALAMIC NUCLEUS; SUICIDAL BEHAVIOR; SURGICAL RISK; TREATMENT RESPONSE;

DEEP BRAIN STIMULATION; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE; RISK FACTORS; SUBTHALAMIC NUCLEUS;

EID: 84884161075     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70151-0     Document Type: Note

References (94)

1. Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011, 26(suppl 3):S2-41.
2. Fasano A, Daniele A, Albanese A Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol 2012, 11:429-442.
3. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006, 355:896-908.
4. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010, 9:581-591.
5. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010, 362:2077-2091.
6. Okun MS, Gallo BV, Mandybur G, et al. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol 2012, 11:140-149.
7. Odekerken VJ, van Laar T, Staal MJ, et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 2013, 12:37-44.
8. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006, 21(suppl 14):S290-S304.
9. Welter ML, Houeto JL, Tezenas du Montcel S, et al. Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 2002, 125:575-583.
10. Charles PD, Van Blercom N, Krack P, et al. Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 2002, 59:932-934.
11. Herzog J, Volkmann J, Krack P, et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord 2003, 18:1332-1337.
12. Schupbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013, 368:610-622.
13. Deuschl G, Schupbach M, Knudsen K, et al. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord 2013, 19:56-61.
14. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009, 301:63-73.
15. Krack P, Hariz MI Parkinson disease: deep brain stimulation in Parkinson disease-what went wrong?. Nat Rev Neurol 2010, 6:535-536.
16. Hoehn MM, Yahr MD Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
17. Gervais-Bernard H, Xie-Brustolin J, Mertens P, et al. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up. J Neurol 2009, 256:225-233.
18. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003, 349:1925-1934.
19. Moro E, Lozano AM, Pollak P, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord 2010, 25:578-586.
20. Piboolnurak P, Lang AE, Lozano AM, et al. Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord 2007, 22:990-997.
21. Romito LM, Contarino MF, Vanacore N, Bentivoglio AR, Scerrati M, Albanese A Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: long-term observation. Mov Disord 2009, 24:557-563.
22. Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005, 76:1640-1644.
23. Simonin C, Tir M, Devos D, et al. Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon. J Neurol 2009, 256:1736-1741.
24. Wider C, Pollo C, Bloch J, Burkhard PR, Vingerhoets FJ Long-term outcome of 50 consecutive Parkinson's disease patients treated with subthalamic deep brain stimulation. Parkinsonism Relat Disord 2008, 14:114-119.
25. Fasano A, Romito LM, Daniele A, et al. Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 2010, 133:2664-2676.
26. Zibetti M, Merola A, Rizzi L, et al. Beyond nine years of continuous subthalamic nucleus deep brain stimulation in Parkinson's disease. Mov Disord 2011, 26:2327-2334.
27. Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, Moro E Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011, 68:1550-1556.
28. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010, 25:2649-2653.
29. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008, 23:837-844.
30. Rodriguez-Oroz MC, Moro E, Krack P Long-term outcomes of surgical therapies for Parkinson's disease. Mov Disord 2012, 27:1718-1728.
31. Schrag A, Jahanshahi M, Quinn N How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000, 15:1112-1118.
32. Maetzler W, Liepelt I, Berg D Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009, 8:1158-1171.
33. Martinez-Martin P, Carod-Artal FJ, da Silveira Ribeiro L, et al. Longitudinal psychometric attributes, responsiveness, and importance of change: an approach using the SCOPA-psychosocial questionnaire. Mov Disord 2008, 23:1516-1523.
34. Klotsche J, Reese JP, Winter Y, et al. Trajectory classes of decline in health-related quality of life in Parkinson's disease: a pilot study. Value Health 2011, 14:329-338.
35. Peto V, Jenkinson C, Fitzpatrick R PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998, 245(suppl 1):S10-S14.
36. Martinez-Martin P, Deuschl G Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease. Mov Disord 2007, 22:757-765.
37. Doshi PK Long-term surgical and hardware-related complications of deep brain stimulation. Stereotact Funct Neurosurg 2011, 89:89-95.
38. Kimmelman J, Duckworth K, Ramsay T, Voss T, Ravina B, Emborg ME Risk of surgical delivery to deep nuclei: a meta-analysis. Mov Disord 2011, 26:1415-1421.
39. Blomstedt P, Bjartmarz H Intracerebral infections as a complication of deep brain stimulation. Stereotact Funct Neurosurg 2012, 90:92-96.
40. Zrinzo L, Foltynie T, Limousin P, Hariz MI Reducing hemorrhagic complications in functional neurosurgery: a large case series and systematic literature review. J Neurosurg 2012, 116:84-94.
41. Voges J, Hilker R, Botzel K, et al. Thirty days complication rate following surgery performed for deep-brain-stimulation. Mov Disord 2007, 22:1486-1489.
42. Williams AE, Arzola GM, Strutt AM, Simpson R, Jankovic J, York MK Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord 2011, 17:321-327.
43. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008, 7:605-614.
44. Witt K, Granert O, Daniels C, et al. Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trial. Brain (in press).
45. Vergani F, Landi A, Pirillo D, Cilia R, Antonini A, Sganzerla EP Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease. World Neurosurg 2010, 73:338-344.
46. Falowski S, Ooi YC, Smith A, Verhargen Metman L, Bakay RA An evaluation of hardware and surgical complications with deep brain stimulation based on diagnosis and lead location. Stereotact Funct Neurosurg 2012, 90:173-180.
47. Guridi J, Rodriguez-Oroz MC, Alegre M, Obeso JA Hardware complications in deep brain stimulation: electrode impedance and loss of clinical benefit. Parkinsonism Relat Disord 2012, 18:765-769.
48. Anheim M, Fraix V, Chabardes S, Krack P, Benabid AL, Pollak P Lifetime of Itrel II pulse generators for subthalamic nucleus stimulation in Parkinson's disease. Mov Disord 2007, 22:2436-2439.
49. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2011, 68:165.
50. Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010, 133:1111-1127.
51. Voon V, Kubu C, Krack P, Houeto JL, Troster AI Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006, 21(suppl 14):S305-S327.
52. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain 2008, 131:2720-2728.
53. Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013, 136:1568-1577.
54. Volkmann J, Daniels C, Witt K Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol 2010, 6:487-498.
55. Krack P, Hariz MI, Baunez C, Guridi J, Obeso JA Deep brain stimulation: from neurology to psychiatry?. Trends Neurosci 2010, 33:474-484.
56. Moum SJ, Price CC, Limotai N, et al. Effects of STN and GPi deep brain stimulation on impulse control disorders and dopamine dysregulation syndrome. PLoS One 2012, 7:e29768.
57. Lhommee E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012, 135:1463-1477.
58. Lim SY, O'Sullivan SS, Kotschet K, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009, 16:1148-1152.
59. Bannier S, Montaurier C, Derost PP, et al. Overweight after deep brain stimulation of the subthalamic nucleus in Parkinson disease: long term follow-up. J Neurol Neurosurg Psychiatry 2009, 80:484-488.
60. Chaudhuri KR, Schapira AH Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009, 8:464-474.
61. Allert N, Markou M, Miskiewicz AA, Nolden L, Karbe H Electrode dysfunctions in patients with deep brain stimulation: a clinical retrospective study. Acta Neurochir (Wien) 2011, 153:2343-2349.
62. Volkmann J, Moro E, Pahwa R Basic algorithms for the programming of deep brain stimulation in Parkinson's disease. Mov Disord 2006, 21(suppl 14):S284-S289.
63. Okun MS, Tagliati M, Pourfar M, et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol 2005, 62:1250-1255.
64. Agid Y, Schupbach M, Gargiulo M, et al. Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so?. J Neural Transm Suppl 2006, 70:409-414.
65. Schupbach M, Gargiulo M, Welter ML, et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body?. Neurology 2006, 66:1811-1816.
66. Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013, 12:264-274.
67. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005, 128:1247-1258.
68. Schupbach WM, Maltete D, Houeto JL, et al. Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology 2007, 68:267-271.
69. Weintraub D, Duda J, Carlson K, et al. Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2013, published online May 10. 10.1136/jnnp-2012-304396.
70. Schapira AH, Olanow CW Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004, 291:358-364.
71. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993, 52:1-6.
72. Agid Y, Ruberg M, Javoy-Agid G, et al. Are dopaminergic neurons selectively vulnerable to Parkinson's disease?. Parkinson's disease: from basic research to treatment 1993, 148-164. Raven Press, New York. H. Narabayashi, T. Nagatsu, N. Yanagisawa, Y. Mizuno (Eds.).
73. Hirsch EC, Jenner P, Przedborski S Pathogenesis of Parkinson's disease. Mov Disord 2013, 28:24-30.
74. Olanow CW, Brundin P Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?. Mov Disord 2013, 28:31-40.
75. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993, 13:4181-4192.
76. Bergman H, Wichmann T, DeLong MR Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990, 249:1436-1438.
77. Wichmann T, DeLong MR, Guridi J, Obeso JA Milestones in research on the pathophysiology of Parkinson's disease. Mov Disord 2011, 26:1032-1041.
78. Maesawa S, Kaneoke Y, Kajita Y, et al. Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats: neuroprotection of dopaminergic neurons. J Neurosurg 2004, 100:679-687.
79. Harnack D, Meissner W, Jira JA, Winter C, Morgenstern R, Kupsch A Placebo-controlled chronic high-frequency stimulation of the subthalamic nucleus preserves dopaminergic nigral neurons in a rat model of progressive parkinsonism. Exp Neurol 2008, 210:257-260.
80. Carvalho GA, Nikkhah G Subthalamic nucleus lesions are neuroprotective against terminal 6-OHDA-induced striatal lesions and restore postural balancing reactions. Exp Neurol 2001, 171:405-417.
81. Piallat B, Benazzouz A, Benabid AL Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioural and immunohistochemical studies. Eur J Neurosci 1996, 8:1408-1414.
82. Shaw VE, Keay KA, Ashkan K, Benabid AL, Mitrofanis J Dopaminergic cells in the periaqueductal grey matter of MPTP-treated monkeys and mice; patterns of survival and effect of deep brain stimulation and lesion of the subthalamic nucleus. Parkinsonism Relat Disord 2010, 16:338-344.
83. Shaw VE, Spana S, Ashkan K, et al. Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment. J Comp Neurol 2010, 518:25-40.
84. Wallace BA, Ashkan K, Heise CE, et al. Survival of midbrain dopaminergic cells after lesion or deep brain stimulation of the subthalamic nucleus in MPTP-treated monkeys. Brain 2007, 130:2129-2145.
85. Hilker R, Portman AT, Voges J, et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry 2005, 76:1217-1221.
86. Toft M, Lilleeng B, Ramm-Pettersen J, et al. Long-term efficacy and mortality in Parkinson's disease patients treated with subthalamic stimulation. Mov Disord 2011, 26:1931-1934.
87. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011, 26:399-406.
88. Chaudhuri KR, Rojo JM, Schapira AH, et al. A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One 2013, 8:e57221.
89. Martinez-Martin P Instruments for holistic assessment of Parkinson's disease. J Neural Transm 2013, 120:559-564.
90. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011, 10:415-423.
91. Schupbach MW, Welter ML, Bonnet AM, et al. Mortality in patients with Parkinson's disease treated by stimulation of the subthalamic nucleus. Mov Disord 2007, 22:257-261.
92. Coelho M, Ferreira JJ Late-stage Parkinson disease. Nat Rev Neurol 2012, 8:435-442.
93. Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010, 133:1755-1762.
94. Tanner CM A second honeymoon for Parkinson's disease?. N Engl J Med 2013, 368:675-676.